Cargando…
Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension
We have been developing an angiotensin II vaccine for hypertension. We conducted a placebo-controlled dose escalation study to investigate the safety, tolerability, and immunological responses of this angiotensin II vaccine (AGMG0201). AGMG0201 was administered to participants with mild to moderate...
Autores principales: | Nakagami, Hironori, Ishihama, Tetsuya, Daikyoji, Yuichi, Sasakura, Chieka, Yamada, Ei, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668431/ https://www.ncbi.nlm.nih.gov/pubmed/34657138 http://dx.doi.org/10.1038/s41440-021-00755-6 |
Ejemplares similares
-
Peptide Vaccines for Hypertension and Diabetes Mellitus
por: Nakagami, Hironori, et al.
Publicado: (2014) -
Recent Progress in Therapeutic Angiogenesis
por: Nakagami, Hironori, et al.
Publicado: (2007) -
Silver trimagnesium phosphate bis(hydrogenphosphate), AgMg(3)(PO(4))(HPO(4))(2), with an alluaudite-like structure
por: Assani, Abderrazzak, et al.
Publicado: (2010) -
Gene Therapy and Cell-Based Therapies for Therapeutic Angiogenesis in Peripheral Artery Disease
por: Shimamura, Munehisa, et al.
Publicado: (2013) -
Lymphedema and Therapeutic Lymphangiogenesis
por: Saito, Yukihiro, et al.
Publicado: (2013)